181 related articles for article (PubMed ID: 10080069)
1. Topoisomerase-I inhibitors in gynecologic tumors.
Haluska P; Rubin E; Verschraegen CF
Hematol Oncol Clin North Am; 1999 Feb; 13(1):43-61, vii-viii. PubMed ID: 10080069
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase-I inhibitors in gynaecologic tumours.
Verschraegen CF; Kudelka AP; Kavanagh JJ
Ann Acad Med Singap; 1998 Sep; 27(5):683-7. PubMed ID: 9919340
[TBL] [Abstract][Full Text] [Related]
3. [New drugs. Topoisomerase inhibitors].
Gutzler F
Zentralbl Gynakol; 1996; 118(10):579. PubMed ID: 8999716
[No Abstract] [Full Text] [Related]
4. Camptothecins: new enthusiasm for an old drug.
Rowe PM
Lancet; 1996 Mar; 347(9005):892. PubMed ID: 8622402
[No Abstract] [Full Text] [Related]
5. Irinotecan in cervical cancer.
Kavanagh JJ; Verschraegen CF; Kudelka AP
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):94-8. PubMed ID: 9726099
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan for the treatment of cervical cancer.
Verschraegen CF
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):32-4. PubMed ID: 12109804
[TBL] [Abstract][Full Text] [Related]
7. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Lavergne O; Bigg DC
Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
Kim DK; Lee N
Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan in epithelial ovarian cancer.
Gershenson DM
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):29-31. PubMed ID: 12109803
[TBL] [Abstract][Full Text] [Related]
10. [DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view].
Taguchi T
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1574-8. PubMed ID: 1651685
[TBL] [Abstract][Full Text] [Related]
11. Clinical applications of the camptothecins.
Takimoto CH; Wright J; Arbuck SG
Biochim Biophys Acta; 1998 Oct; 1400(1-3):107-19. PubMed ID: 9748525
[TBL] [Abstract][Full Text] [Related]
12. Camptothecins in clinical development.
Zunino F; Pratesi G
Expert Opin Investig Drugs; 2004 Mar; 13(3):269-84. PubMed ID: 15013945
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic approach for colorectal cancer with topoisomerase as a molecular target].
Tsunoda T
Nihon Rinsho; 2003 Sep; 61 Suppl 7():472-5. PubMed ID: 14574938
[No Abstract] [Full Text] [Related]
14. [Clinical activity spectrum of irinotecan].
Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase-I inhibitors in the management of colon cancer.
Willson JK
Ann N Y Acad Sci; 1996 Dec; 803():256-63. PubMed ID: 8993519
[No Abstract] [Full Text] [Related]
16. Schedule-dependent efficacy of camptothecins in models of human cancer.
Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA
Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512
[No Abstract] [Full Text] [Related]
17. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile.
Hartmann JT; Lipp HP
Drug Saf; 2006; 29(3):209-30. PubMed ID: 16524321
[TBL] [Abstract][Full Text] [Related]
19. CPT-11: an original spectrum of clinical activity.
Rothenberg ML
Semin Oncol; 1996 Feb; 23(1 Suppl 3):21-6. PubMed ID: 8633249
[TBL] [Abstract][Full Text] [Related]
20. [Irinotecan in colorectal cancer].
Pozzo C; Cassano A; Barone C
Tumori; 2001; 87(1 Suppl 1):S49-50. PubMed ID: 11300023
[No Abstract] [Full Text] [Related]
[Next] [New Search]
